Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene.
T-cell post-transplant lymphoproliferative disorder (PTLD) is a rare life threatening complication of organ transplantation. It is usually resistant to treatment with reduction in immunosuppression or chemotherapy and carries a poor prognosis. We report on a combined kidney and pancreas transplant patient with Epstein-Barr virus (EBV) positive T-cell PTLD that had recurred after chemotherapy and reduction in immunosuppression. The patient was successfully treated with bexarotene, a novel synthetic retinoid analog, achieving a complete clinical response. Bexarotene may be a promising treatment for T-cell PTLD.
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA. detsai@mail.med.upenn.edu
Donald E
DE
Tsai
Nicole A
NA
Aqui
Dan T
DT
Vogl
Roy D
RD
Bloom
Stephen J
SJ
Schuster
Sunita D
SD
Nasta
Mariusz A
MA
Wasik
D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000077610:Bexarotene; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000175:diagnosis; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000009:adverse effects*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use; D019562:Viral Load
D016588:Anticarcinogenic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene